EUVIMEDEUVIMED entdecken
Crossref

2429-P: Unlicensed vs. Licensed Mesenchymal Stromal Cells: Impact on Subcutaneous Vascularization and Neonatal Porcine Islet Engraftment and Function

NEREA CUESTA GOMEZ, ARGHYADIP BOSE, PURUSHOTHAMAN KUPPAN, JOY PARAMOR, CHELSEA CASTRO, MANDY ROSKO, ANDREW PEPPER, GREG S. KORBUTT

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2429-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von NEREA CUESTA GOMEZ und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Islet transplantation can reverse hyperglycaemia, but poor engraftment limits long-term success. The subcutaneous (SC) space is accessible but poorly vascularized, limiting islet survival. Mesenchymal stromal cells (MSCs) enhance angiogenesis; cytokine exposure (licensing) further enhances their potential. We aimed to determine if unlicensed or licensed MSCs improve SC vascularization and neonatal porcine islet (NPI) engraftment and diabetes reversal.

Methods

Human pancreatic MSCs were unmodified or licensed for 24h with TNF-α, IL-1β, and IFN-γ (10 ng/mL). PLGA+gelatin (PLGA+G) scaffolds were implanted SC as controls or coated with 5×106 MSCs: unlicensed (PGM) or licensed (PGSM). Vascularization was assessed 2 weeks post-implantation by FITC-lectin injection. Streptozotocin-diabetic immunodeficient mice received 3000 NPIs into the pre-vascularized niche. Efficacy outcomes included vascular metrics and diabetes reversal; ANOVA and log-rank tests were applied.

Results

Licensing increased MSC expression of CXCL1/5/6/8, FGF2, and VEGF (all p<0.01). PGM and PGSM increased vessel area/mm² (PGM p=0.0138; PGSM p<0.0001) and vessel number/mm² (PGM p=0.0011; PGSM p<0.0001) versus PLGA+G, with PGSM being significantly higher than PGM for all metrics. Lectin+ (PGM p=0.0029; PGSM p<0.0001), CD31+ (PGM p<0.0001; PGSM p<0.0001), and SMA+ cells (PGM p<0.0001; PGSM p<0.0001) followed the same pattern. PGM improved diabetes reversal (10/12 vs 4/12 in PLGA+G; p=0.0139) and reduced reversal time (14 vs 22 weeks; p=0.0177). PGSM did not improve diabetes reversal (p>0.05) compared to PLGA+G.

Conclusion

Both PGM and PGSM enhanced SC vascularization, with PGSM producing the highest vascular density. However, only PGM improved NPI engraftment and diabetes reversal, indicating that further work is needed to translate vascular gains into functional improvements. These findings support the use of MSCs to enhance SC transplantation for diabetes therapy. Disclosure N. Cuesta Gomez: None. A. Bose: None. P. Kuppan: None. J. Paramor: None. C. Castro: None. M. Rosko: None. A. Pepper: Consultant; Current; Encellin, Inc. Stock/Shareholder; Current; Transcyto Therapeutics. G.S. Korbutt: None.

Zitieren

APA

GOMEZ, N. C., BOSE, A., KUPPAN, P., PARAMOR, J., CASTRO, C., ROSKO, M., PEPPER, A., & KORBUTT, G. S. (2026). 2429-P: Unlicensed vs. Licensed Mesenchymal Stromal Cells: Impact on Subcutaneous Vascularization and Neonatal Porcine Islet Engraftment and Function. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2429-p

Vancouver

GOMEZ NC, BOSE A, KUPPAN P, PARAMOR J, CASTRO C, ROSKO M, et al. 2429-P: Unlicensed vs. Licensed Mesenchymal Stromal Cells: Impact on Subcutaneous Vascularization and Neonatal Porcine Islet Engraftment and Function. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2429-p

BibTeX
@article{GOMEZ2026,
  author = {GOMEZ, NEREA CUESTA and BOSE, ARGHYADIP and KUPPAN, PURUSHOTHAMAN and PARAMOR, JOY and CASTRO, CHELSEA and ROSKO, MANDY and PEPPER, ANDREW and KORBUTT, GREG S.},
  title = {2429-P: Unlicensed vs. Licensed Mesenchymal Stromal Cells: Impact on Subcutaneous Vascularization and Neonatal Porcine Islet Engraftment and Function},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2429-p}
}
Kostenlos starten →